Abeona Therapeutics vs Rocket Pharmaceuticals
ABEO and RCKT side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ABEO and RCKT compare
Rocket Pharmaceuticals is the larger company, worth 1.6 times as much as Abeona Therapeutics ($232M against $149M).
Abeona Therapeutics scores higher on the StockData Score (8 against 3 for Rocket Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ABEO | RCKT |
|---|---|---|
| Size and price | ||
| Market cap | $149M | $232M |
| Share price | $2.60 | $2.11 |
| Change, 1 year | −41.6% | −30.8% |
| Change, 5 years | −85.8% | −91.1% |
| Beta (5Y) | 1.71 | 2.32 |
| Employees | 226 | 202 |
| StockData Score | ||
| Total score | 8 (better) | 3 |
| Valuation score | 3 (better) | 1 |
| Growth score | 1 (better) | 0 |
| Performance score | 2 (better) | 1 |
| Health score | 2 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 5.8× | – |
| P/B | 1.2× | 0.6× (better) |
| FCF yield | −54.8% (better) | −73.6% |
| Fair value | $3.58 | – |
| Margin of safety | 27.4% | – |
| Growth | ||
| Revenue growth, 5Y average | −10.3% | – |
| Net income growth (TTM) | −210% | – |
| Profitability | ||
| Gross margin | 67.1% | – |
| Operating margin | −328% | – |
| Net margin | −246% | – |
| FCF margin | −319% | – |
| Return on equity | −43.1% | −4.8% (better) |
| Return on invested capital | – | −180% |
| Financial health | ||
| Debt / equity | 0.12 | – |
| Interest coverage | −25.3× (better) | −101.3× |
| Current ratio | 6.63 | 9.24 (better) |
| Altman Z-score | −4.80 | −2.72 (better) |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 77.9% | 90.9% |
| Held by insiders | 12.3% | 22.3% |
| Insider net buying, 12 months | −$3.5M | −$934K (better) |
| Short interest, % of float | 33.7% | 19.0% |
Go deeper
- ABEO stock overview
- ABEO income statement
- ABEO valuation and score
- RCKT stock overview
- RCKT income statement
- RCKT valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.